Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial

Saad Z. Usmani, Antje Hoering, Sikander Ailawadhi, Rachael Sexton, Brea Lipe, Sandi Hita, Jason Valent, Michael Rosenzweig, Jeffrey A. Zonder, Madhav V. Dhodapkar, Natalie S. Callander, Todd M. Zimmerman, Peter M. Voorhees, Brian G.M. Durie, S. Vincent Rajkumar, Paul G. Richardson, Robert Z. Orlowski